Literature DB >> 25375049

Is surgical treatment of liver hemangiomas effective for pain relief?

E G Dumlu, O Abbasoglu, E Hamaloglu.   

Abstract

BACKGROUND: Traditional treatment for liver hemangiomas is surgery. Currently, it is controversial whether hemangioma surgeries are sufficiently beneficial for the patients. In this study, we evaluated the effectiveness of surgery in patients with liver hemangiomas.
METHODS: Forty-two patients who underwent surgical operations for hepatic hemangiomas were retrospectively evaluated and interviewed.
RESULTS: Study population included 36 female and 6 male patients whose ages ranged between 26 and 65 years (mean age, 47.8 +-8.7 years). Their mean duration of hospitalization was 6 days (range, 3 - 59 days). The median time since surgery was 50 months (range 0-120 months). There was a statistically significant decrease in numerical rating and adjective rating pain scale scores (p 0.05). Postoperatively, pain did not cease in 10 patients (peptic ulcers requiring medical treatment in four patients, cholelithiasis in four patients, and nephrolithiasis in two patients).
CONCLUSION: Patients with cavernous hemangiomas of the liver who require surgical treatment have significant benefits in terms of pain relief following surgery. The lack of pain relief after the surgery in some patients may be related to concomitant medical problems other than the hemangioma. Celsius.

Entities:  

Mesh:

Year:  2014        PMID: 25375049

Source DB:  PubMed          Journal:  Chirurgia (Bucur)        ISSN: 1221-9118


  2 in total

1.  Management of liver hemangioma using trans-catheter arterial embolization.

Authors:  Kavous Firouznia; Hossein Ghanaati; Seyed Moayed Alavian; Mohssen Nassiri Toosi; Nasser Ebrahimi Daryani; Amir Hossein Jalali; Madjid Shakiba; Sima Hosseinverdi
Journal:  Hepat Mon       Date:  2014-12-25       Impact factor: 0.660

2.  Surgical indication and strategy for liver hemangioma in the caudate lobe: a multi-institutional retrospective analysis with 137 patients.

Authors:  Wei Long Cai; Xiao Ming Ma; Xu Heng Sun; Tai Ren; Cong Yun Huang; Yong Sheng Li; Xu An Wang; Ying Bin Liu; Shu You Peng
Journal:  World J Surg Oncol       Date:  2020-06-10       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.